PNC Financial Services Group
SUPN icon

PNC Financial Services Group’s Supernus Pharmaceuticals SUPN Stock Holding History

PNC Financial Services Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$752K Buy
14,548
+321
+2% +$16.3K ﹤0.01% 1439
2025
Q4 		$707K Sell
14,227
-1,331
-9% -$64.7K ﹤0.01% 1438
2025
Q3 		$744K Sell
15,558
-313
-2% -$12.6K ﹤0.01% 1405
2025
Q2 		$500K Sell
15,871
-226
-1% -$7.24K ﹤0.01% 1562
2025
Q1 		$527K Buy
16,097
+726
+5% +$25.7K ﹤0.01% 1478
2024
Q4 		$556K Sell
15,371
-362
-2% -$12.7K ﹤0.01% 1468
2024
Q3 		$491K Sell
15,733
-1,377
-8% -$43K ﹤0.01% 1544
2024
Q2 		$458K Sell
17,110
-2,873
-14% -$83.3K ﹤0.01% 1552
2024
Q1 		$682K Sell
19,983
-2,205
-10% -$65.7K ﹤0.01% 1338
2023
Q4 		$642K Buy
22,188
+246
+1% +$6.52K ﹤0.01% 1365
2023
Q3 		$605K Sell
21,942
-3,467
-14% -$106K ﹤0.01% 1377
2023
Q2 		$764K Sell
25,409
-200
-0.8% -$7K ﹤0.01% 1296
2023
Q1 		$928K Sell
25,609
-50
-0.2% -$1.92K ﹤0.01% 1180
2022
Q4 		$915K Sell
25,659
-5,327
-17% -$185K ﹤0.01% 1170
2022
Q3 		$1.05M Sell
30,986
-1,246
-4% -$40.5K ﹤0.01% 1105
2022
Q2 		$932K Buy
32,232
+1,002
+3% +$28.7K ﹤0.01% 1196
2022
Q1 		$1.01M Sell
31,230
-1,059
-3% -$32.5K ﹤0.01% 1241
2021
Q4 		$940K Buy
32,289
+8,206
+34% +$249K ﹤0.01% 1315
2021
Q3 		$642K Buy
24,083
+1,984
+9% +$53.3K ﹤0.01% 1462
2021
Q2 		$680K Buy
22,099
+2,222
+11% +$68.1K ﹤0.01% 1423
2021
Q1 		$520K Buy
19,877
+11,054
+125% +$309K ﹤0.01% 1538
2020
Q4 		$222K Buy
8,823
+678
+8% +$14.6K ﹤0.01% 2005
2020
Q3 		$170K Buy
8,145
+1,605
+25% +$36.4K ﹤0.01% 2026
2020
Q2 		$155K Buy
6,540
+4,675
+251% +$103K ﹤0.01% 2067
2020
Q1 		$33K Sell
1,865
-963
-34% -$20.2K ﹤0.01% 2865
2019
Q4 		$67K Sell
2,828
-17,220
-86% -$418K ﹤0.01% 2723
2019
Q3 		$551K Sell
20,048
-72,541
-78% -$2.15M ﹤0.01% 1545
2019
Q2 		$3.06M Sell
92,589
-50,765
-35% -$1.74M ﹤0.01% 856
2019
Q1 		$5.02M Sell
143,354
-47,087
-25% -$1.75M 0.01% 707
2018
Q4 		$6.33M Sell
190,441
-15,414
-7% -$663K 0.01% 610
2018
Q3 		$10.4M Sell
205,855
-2,682
-1% -$132K 0.01% 534
2018
Q2 		$12.5M Sell
208,537
-1,604
-0.8% -$83.1K 0.01% 487
2018
Q1 		$9.62M Sell
210,141
-1,856
-0.9% -$77.5K 0.01% 538
2017
Q4 		$8.45M Sell
211,997
-12,844
-6% -$508K 0.01% 565
2017
Q3 		$8.99M Sell
224,841
-24,343
-10% -$1.05M 0.01% 537
2017
Q2 		$10.7M Buy
249,184
+12,210
+5% +$435K 0.01% 502
2017
Q1 		$7.42M Sell
236,974
-25,270
-10% -$677K 0.01% 565
2016
Q4 		$6.62M Buy
262,244
+13,442
+5% +$300K 0.01% 598
2016
Q3 		$6.15M Buy
248,802
+225,806
+982% +$5.11M 0.01% 606
2016
Q2 		$468K Sell
22,996
-44
-0.2% -$780 ﹤0.01% 1585
2016
Q1 		$352K Sell
23,040
-82,443
-78% -$1.08M ﹤0.01% 1750
2015
Q4 		$1.42M Sell
105,483
-19,093
-15% -$295K ﹤0.01% 1057
2015
Q3 		$1.75M Buy
124,576
+57,190
+85% +$1.06M ﹤0.01% 1001
2015
Q2 		$1.14M Buy
+67,386
New +$959K ﹤0.01% 1219

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's SUPN Position: Q1 2026 in Review

PNC Financial Services Group increased its Supernus Pharmaceuticals (SUPN) stake by 2.3% in Q1 2026, buying an estimated $16.3K and bringing the position to 14,548 shares worth $752K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

PNC Financial Services Group first reported a position in SUPN in Q2 2015 and has held it in 44 quarters since. The position peaked at $12.5M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • PNC Financial Services Group held 14,548 shares of Supernus Pharmaceuticals worth $752K as of Q1 2026.
  • PNC Financial Services Group bought 321 Supernus Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
  • Supernus Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #1439 holding.
  • PNC Financial Services Group first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • PNC Financial Services Group's Supernus Pharmaceuticals position peaked at $12.5M in Q2 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.